BTIG Maintains Buy on Exact Sciences, Lowers Price Target to $70
BTIG analyst Mark Massaro maintains Exact Sciences (NASDAQ:EXAS) with a Buy and lowers the price target from $100 to $70.
Raymond James Maintains Outperform on Exact Sciences, Lowers Price Target to $70
Raymond James analyst Andrew Cooper maintains Exact Sciences (NASDAQ:EXAS) with a Outperform and lowers the price target from $80 to $70.
Exact Sciences Q2 EPS $(0.90) Beats $(1.07) Estimate, Sales $521.64M Beat $497.50M Estimate
Exact Sciences (NASDAQ:EXAS) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate of $(1.07) by 15.89 percent. This is a 12.62 percent increase over losses of $(1.03) per share from
Mdxhealth Acquires Oncotype DX GPS Prostate Cancer Business From Exact Sciences For Aggregate Purchase Price Of Up To $100M
Under the terms of the asset purchase agreement, mdxhealth acquired the Oncotype DX GPS prostate cancer business of Exact Sciences for an aggregate purchase price of up to $100 million, of which an amount of $25 million
Earnings Scheduled For August 2, 2022
Companies Reporting Before The Bell
• Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Ultima Genomics And Exact Sciences Enter Long-Term Supply Agreement
Ultima Genomics, Inc. and Exact Sciences Corporation (NASDAQ:EXAS) have entered a long-term supply agreement for Ultima's next-generation sequencing (NGS) technologies. Under the terms of the supply agreement,
Piper Sandler Initiates Coverage On Exact Sciences with Neutral Rating, Announces Price Target of $50
Piper Sandler analyst David Westenberg initiates coverage on Exact Sciences (NASDAQ:EXAS) with a Neutral rating and announces Price Target of $50.
9 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
